Merck Stock Seeks $200 Threshold Amid Regulatory and Clinical Hurdles
Merck's stock has surged 19% in a month and is up 45% year-to-date, making it one of the strongest large-cap pharma runs this year. The company's shares are trading at $156 after reaching a high of $155.99.
The near-term case for Merck stock reaching $200 depends on a compressed run of regulatory and clinical events this fall. Key catalysts include the PDUFA dates in September and October, which could unlock estimate revisions across Merck's oncology franchise. The company's cancer vaccine partner, Moderna, is also expected to report positive results from its Phase 3 adjuvant melanoma interim analysis by the end of 2026.
Merck CEO Robert Davis has downplayed concerns about the patent cliff facing KEYTRUDA, saying it's 'more of a hill than a cliff.' He projects over $70 billion in opportunity from 20-plus pipeline products. However, analysts remain cautious, and the company faces challenges from larger peer Pfizer and mRNA oncology developer BioNTech SE.